BiotechTube

EVRA transdermal contraceptive patch 6 mg NGMN and 0.75 mg EE

Phase 1Completed
0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Contraception

Conditions

Contraception, Female Contraception

Trial Timeline

Apr 1, 2004 → Sep 1, 2004

NCT ID
NCT00258076

About EVRA transdermal contraceptive patch 6 mg NGMN and 0.75 mg EE

EVRA transdermal contraceptive patch 6 mg NGMN and 0.75 mg EE is a phase 1 stage product being developed by Johnson & Johnson for Contraception. The current trial status is completed. This product is registered under clinical trial identifier NCT00258076. Target conditions include Contraception, Female Contraception.

What happened to similar drugs?

15 of 20 similar drugs in Contraception were approved

Approved (15) Terminated (1) Active (5)
✅Etonogestrel contraceptive implantMerckApproved
✅Rifampin 600 MGMerckApproved
✅Long Acting Reversible Contraception (LARC)MerckApproved
✅Etonogestrel contraceptive implantMerckApproved
✅Sayana PressPfizerApproved
✅Depo-Provera Contraceptive Injection - DP150CIPfizerApproved
✅Subcutaneous depot medroxyprogesterone acetatePfizerApproved

Hype Score Breakdown

Clinical
6
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00258076Phase 1Completed

Competing Products

20 competing products in Contraception

See all competitors
ProductCompanyStageHype Score
Injection CyclofemSun PharmaceuticalPhase 1/2
32
Relugolix Combination TherapySumitomo PharmaPhase 3
44
Transdermal Contraceptive System + Norgestimate-containing oral contraceptives with EEJohnson & JohnsonPre-clinical
26
norelgestromin/ethinyl estradiol (NGMN/EE) transdermal contraceptive system.Johnson & JohnsonPhase 1
29
norelgestromin + ethinyl estradiolJohnson & JohnsonPhase 3
40
norelgestromin + ethinyl estradiol; triphasil.Johnson & JohnsonPhase 3
40
norelgestromin + ethinyl estradiol; mercilonJohnson & JohnsonPhase 3
40
EVRA® transdermal contraceptive patch containing 6 mg of norelgestromin and 0.60 mg of ethinyl estradiol (versus CILEST® tablets).Johnson & JohnsonPhase 1
29
Monophasic or triphasic Oral contraceptive tablet + Ortho Evra transdermal patch containing 6 mg NGMN/0.75 mg EEJohnson & JohnsonPre-clinical
26
Norgestimate/Ehinyl Estradiol; Folic acid.Johnson & JohnsonPhase 1
29
EVRA® transdermal contraceptive patch containing 6 mg of norelgestromin and 0.75 mg of ethinyl estradiol (versus CILEST® tablets).Johnson & JohnsonPhase 1
29
oral ulipristal acetateMerckPhase 1
29
Etonogestrel contraceptive implantMerckApproved
43
Rifampin 600 MGMerckApproved
43
Long Acting Reversible Contraception (LARC)MerckApproved
35
Etonogestrel contraceptive implantMerckApproved
43
Medroxyprogesterone 17-Acetate + Medroxyprogesterone 17-AcetatePfizerPre-clinical
26
Sayana PressPfizerApproved
43
Levonorgestrel 90 mg/Ethinyl Estradiol 20 mgPfizerPhase 3
40
Depo-Provera Contraceptive Injection - DP150CIPfizerApproved
43